Esomeprazole Na + Cimetidine + Esomeprazole Mg
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bleeding Peptic Ulcer
Conditions
Bleeding Peptic Ulcer
Trial Timeline
Feb 1, 2013 → Dec 1, 2014
NCT ID
NCT01757275About Esomeprazole Na + Cimetidine + Esomeprazole Mg
Esomeprazole Na + Cimetidine + Esomeprazole Mg is a phase 3 stage product being developed by AstraZeneca for Bleeding Peptic Ulcer. The current trial status is completed. This product is registered under clinical trial identifier NCT01757275. Target conditions include Bleeding Peptic Ulcer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01757275 | Phase 3 | Completed |
Competing Products
20 competing products in Bleeding Peptic Ulcer